India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

The company was informed by its contract manufacturer in India, Astral, that it has observed an out-of-specification during a routine envir...

In a letter written to stockists, distributors and hospitals across India, Pfizer has asked for temporary suspension of sale and distributi...

Primcyv is a targeted therapy containing the active constituent palbociclib, a first-in-class CDK 4/6 inhibitor indicated in combination wi...

Pfizer has entered into advance purchase agreements with multiple countries. Sources told ET that Pfizer is yet to apply for emergency use ...

The U.S. company pulled an application last month seeking emergency approval for its product in India after the drug regulator declined its...

On Monday, Pfizer and Mylan announced that as per the Reverse Morris Trust transaction, each Mylan share would be converted into one share ...

After the deal, GSK will have a majority controlling equity interest of 68 per cent in the combined consumer healthcare business.

GSK and Pfizer said on Wednesday they will merge their consumer healthcare businesses, which have combined sales of $12 billion, by creatin...

Although the company sells most of its top 20 global products in India, it is looking to bring in a couple of drugs, the patents of which h...

Competition watchdog CCI has approved Nestle's proposed acquisition of the global nutrition business of Pfizer.

Indian Pharma Co claims it can sell HIV drug at one-fifth the price.

On a plea by global pharma major Pfizer, the Delhi High Court today restrained Ahmedabad-based Stallion Laboratories from manufacturing and...

Pfizer India will hire an additional 200 people in the next few months and will continue to increase its headcount because it sees minimal ...

Pfizer Inc has agreed to license an array of generic pills and injectable medicines from India's Aurobindo Pharma Ltd as the world's larges...

Pfizer's $68-billion buyout of Wyeth may help catapult its local subsidiary into the top ten league of Indian drugmakers.

The acquisition of Pfizer’s global over-the-counter (OTC) business by Johnson & Johnson (J&J) will have some impact on Pfizer India, though...